Compass Pathways Plc ((CMPS)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Compass Pathways Plc is conducting a phase III study titled ‘A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression.’ The study aims to evaluate the effectiveness, safety, and tolerability of COMP360 in adults with treatment-resistant depression (TRD), a condition where patients do not respond to standard treatments. This study is significant as it explores new treatment avenues for TRD, potentially offering hope to patients with limited options.
The intervention being tested is COMP360, a psilocybin-based drug administered in doses of 25 mg, 10 mg, and 1 mg. The purpose of this treatment is to assess its efficacy in alleviating symptoms of depression when used alongside psychological support.
The study design is interventional and involves a randomized, parallel assignment of participants. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all unaware of which treatment the participant is receiving. The primary goal is treatment-focused.
The study began on February 14, 2023, with an estimated completion date in August 2025. The primary completion date is yet to be announced. These timelines are crucial for investors as they indicate when results might impact the market.
This study update could influence Compass Pathways’ stock performance positively, as successful results may boost investor confidence and interest in the company’s innovative approach to treating TRD. Investors should also consider the broader industry context, as other companies are exploring similar psychedelic treatments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.